Paragon BioTeck, Inc.

Paragon BioTeck, Inc. News Room Archive and Profile

Paragon BioTeck, Inc. is a privately held pharmaceutical and medical device company specializing in the development and commercialization of ophthalmic pharmaceuticals, devices and therapies. Paragon BioTeck's portfolio of products is designed to protect and preserve eyesight and deliver comfort to the eyes.

Engage with Paragon BioTeck, Inc.

Learn more online at: https://paragonbioteck.com/

Follow:  Twitter  |  Facebook  |  LinkedIn

RSS News Feed for Paragon BioTeck, Inc.

Press Releases from Paragon BioTeck, Inc. :

Ruling Affirms Patent Claim for Paragon BioTeck’s R-Phenylephrine Hydrochloride Formulation

Paragon BioTeck, Inc.

PORTLAND, Ore., Nov. 21, 2016 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc. announces a monumental ruling handed down by the United States Patent and Trademark Office (USPTO) affirming claims made by Paragon in the patent for its R-phenylephrine hydrochloride formulation. Paragon is a privately held pharmaceutical and medical device company specializing in the development and commercialization of ophthalmic pharmaceuticals, devices and therapies.

Paragon BioTeck, Inc. Announces Call for 2017 Koch Kellan Scholarship Applicants

Paragon BioTeck Gives

PORTLAND, Ore., Sept. 1, 2016 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, announced today a call for applications for the 2017 Koch Kellan Scholarship, awarded annually to an outstanding graduate medical student committed to pursuing a clinical, teaching or research career in ophthalmology. A Paragon Gives initiative, the Koch Kellan Scholarship reinforces the fundamental mission of Paragon BioTeck to drive innovations to address unmet and underserved medical needs and improve the quality of lives around the world.

Hasenin Al-khersan Named 2016 Koch Kellan Scholar

Paragon BioTeck

PORTLAND, Ore., April 18, 2016 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., announced today that Hasenin Al-khersan has been named its 2016 Koch Kellan Scholar. Paragon Gives, a Paragon BioTeck initiative, awards the Koch Kellan Scholarship to an outstanding graduate medical student committed to pursuing a clinical, teaching or research career in ophthalmology.

Paragon BioTeck Receives EN ISO 13485:2012 Certification

Paragon BioTeck

PORTLAND, Ore., March 29, 2016 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, announced today that it has received EN ISO 13485:2012 certification, signifying the company’s successful implementation of an effective quality management system.

Paragon BioTeck to Attend 34th Annual J.P. Morgan Healthcare Conference

Paragon BioTeck

PORTLAND, Ore., Jan. 7, 2016 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, will sponsor a special reception during the J.P. Morgan 2016 Healthcare Conference, being held in San Francisco, January 11-14. The conference, which is now in its 34th year, is an invitation-only event intended to create an environment of collaboration by bringing together stakeholders in the corporate, investor and financial sectors to learn about and explore market and sector trends.

Paragon BioTeck Receives CE Mark Approval on Comfortear Lacrisolve Absorbable Punctum Plug

Paragon BioTeck

PORTLAND, Ore., Nov. 17, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, announced today that it has received CE mark approval for the recently FDA cleared Comfortear(R) Lacrisolve(TM) Absorbable Punctum Plug. CE mark approval is recognized and associated with safety and performance in multiple countries.

Paragon BioTeck, Inc. Announces Corporate Citizenship Initiative, ‘Paragon Gives’

Paragon BioTeck

PORTLAND, Ore., Oct. 16, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, announces that it will be formally launching its corporate citizenship initiative coined, Paragon Gives. On Sunday October 19, 2014, Paragon BioTeck, will kick off its newly branded corporate social responsibility initiative at the annual American Academy of Ophthalmology conference in Chicago, Ill.

Paragon BioTeck to Exhibit at American Academy of Ophthalmology Annual Meeting in Chicago

Paragon BioTeck

PORTLAND, Ore., Oct. 15, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, will be exhibiting at the American Academy of Ophthalmology (Booth #4550) in Chicago, Ill., on October 18 – 21.

Paragon BioTeck, Inc. Receives FDA Clearance for Comfortear Lacrisolve Absorbable Punctum Plug

Paragon BioTeck

PORTLAND, Ore., June 25, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Comfortear(R) Lacrisolve(TM) Absorbable Punctum Plug.

Paragon BioTeck announces FDA Approved Phenylephrine Hydrochloride Ophthalmic Solution Readily Available

Paragon BioTeck

PORTLAND, Ore., June 4, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held U.S. biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, announces its FDA approved Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil, is readily available through Bausch + Lomb or your primary wholesaler.

Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent Readily Available

Paragon BioTeck

PORTLAND, Ore., April 9, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, received FDA approval of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil on March 21, 2013.

Paragon Puts Ilast® Center Stage

Paragon BioTeck

PORTLAND, Ore., Nov. 8, 2013 (SEND2PRESS NEWSWIRE) — Leading biopharmaceutical company Paragon BioTeck, Inc. announced today that it plans to launch its new line of products, known as Ilast(R), at the Annual American Academy of Ophthalmology meeting in New Orleans. Paragon signed an exclusive distribution agreement with Horus Pharma to supply Ilast(R) ocular care products in the U.S. last month, and the company is excited to release these products to ophthalmology professionals.

Paragon BioTeck Signs Exclusive Distribution Agreement with Horus Pharma for Ilast

Paragon BioTeck

PORTLAND, Ore., Oct. 9, 2013 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc. today announced that it has signed a distribution agreement with Horus Pharma for rights to supply the Ilast(R) range of its medical-grade ocular hygiene and lid care products within the United States; it begins on an exclusive basis this month.

Bausch + Lomb Signs Exclusive License Agreement with Paragon BioTeck for Phenylephrine

Paragon BioTeck

MADISON, N.J. and TIGARD, Ore., April 19, 2013 (SEND2PRESS NEWSWIRE) — Bausch + Lomb, the global eye health company and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon’s phenylephrine in the United States on an exclusive basis beginning this month.

Paragon BioTeck, Inc.’s Online Social Networking Platform, Noble Vision Group, Incorporates Treato’s Patient-Generated Medical Database

Paragon BioTeck

TIGARD, Ore., June 14, 2012 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a research and development organization in the eye care industry, today announced that the company’s online community discussion forum and blog, Noble Vision Group, has added the revolutionary plug-in, Treato. The plug-in, released to developers in May, 2012, allows users to search Treato’s database of over 1 billion patient-generated social media posts, providing important insights into the side effects and efficacy of over 11,000 medications.